Zobrazeno 1 - 10
of 86
pro vyhledávání: '"Y van Delft"'
Autor:
Marije Van Schalkwyk, Lerato Mohapi, R Luk, Peter Mugyenyi, RT Schooley, SN Fontain, Beatriz Grinsztejn, Cecilia Kanyama, T Sise, A Collier, R Salata, J Valencia, P Sugandhavesa, BR Santos, Patcharaphan Sugandhavesa, Carole L. Wallis, Breno Santos, R Walensky, R Gross, H Mugerwa, SW Cardoso, J Rooney, Justin Ritz, L Hovind, Sharlaa Faesen, Robert E. Gross, CV Fletcher, L Wieclaw, Evelyn Hogg, A Shahkolahi, M van Schalkwyk, W Samaneka, Y van Delft, John W. Mellors, S Faesen, C Wallis, Aggrey Bukuru, Robert T. Schooley, Anchalee Avihingsanon, N Kumarasamy, J van Wyk, D Kadam, C Godfrey, R Leavitt, Ann C. Collier, R Secours, C Kanyama, Mumbi Makanga, L Nakibuuka, H Nassolo, Wadzanai Samaneka, M Gandhi, Esmelda Montalban, R Mngqibisa, Javier Valencia, P Anthony, Vidya Mave, Rosie Mngqibisa, V Kulkarni, E Hogg, Nagalingeswaran Kumarasamy, V Mave, Robert A. Salata, Catherine Godfrey, A Benns, M Hughes, A Avihingsanon, B Grinsztejn, B Mansfield, PN Mugyenyi, M Nsubuga, M Makanga, Michael Hughes, Sandra W. Cardoso, J Ritz, Linda Wieclaw, Rode Secours, Sandy Nerette Fontain, Beatrice Wangari Ndege, BW Ndege, E Montalban
Publikováno v:
Lancet HIV
Summary Background Antiretroviral therapy (ART) management is challenging for individuals in resource-limited settings presenting for third-line treatment because of complex resistance patterns, partly due to reduced access to viral load monitoring.
Publikováno v:
HIV Medicine. 14:421-429
Objectives Etravirine is a substrate and inducer of cytochrome P450 (CYP) 3A and a substrate and inhibitor of CYP2C9 and CYPC2C19. Darunavir/ritonavir is a substrate and inhibitor of CYP3A. Artemether and lumefantrine are primarily metabolized by CYP
Publikováno v:
HIV Medicine. 14:284-292
Background Individual randomized trials of first-line antiretroviral treatment do not consistently show an association between higher baseline HIV-1 RNA and lower efficacy. Methods A MEDLINE search identified 21 HIV clinical trials with published ana
Autor:
Andrew Hill, Y van Delft, Nathan Clumeck, Mark T. Nelson, Christiane Moecklinghoff, Jose R. Arribas
Publikováno v:
HIV Medicine. 13:398-405
Background In the MONotherapy in Europe with Tmc114 (MONET) trial, darunavir/ritonavir (DRV/r) monotherapy showed noninferior efficacy vs. two nucleoside reverse transcriptase inhibitors (NRTIs) plus DRV/r at the primary 48-week analysis. The trial w
Publikováno v:
International Journal of STD & AIDS. 24:679-681
Background : In previous studies of protease inhibitor (PI) monotherapy, patients with higher nadir CD4 counts, baseline HIV RNA 50 copies/mL. Treatment failure was defined as two consecutive HIV RNA levels >50 copies/mL (TLOVR) by Week 144, or disco
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
K zobrazení výsledku je třeba se přihlásit.
Publikováno v:
HIV medicine. 14(7)
Etravirine is a substrate and inducer of cytochrome P450 (CYP) 3A and a substrate and inhibitor of CYP2C9 and CYPC2C19. Darunavir/ritonavir is a substrate and inhibitor of CYP3A. Artemether and lumefantrine are primarily metabolized by CYP3A; artemet
Publikováno v:
Journal of the International AIDS Society. 15
Background : Switching from triple combination treatment to protease inhibitor (PI) monotherapy may prevent or reverse adverse events related to long-term nucleoside analogues. Lipoatrophy is associated with long-term use of thymidine analogues (zido
Publikováno v:
HIV medicine. 14(5)
Individual randomized trials of first-line antiretroviral treatment do not consistently show an association between higher baseline HIV-1 RNA and lower efficacy.A MEDLINE search identified 21 HIV clinical trials with published analyses of antiretrovi
Autor:
Lorenzo Minoli, M. Stoll, M. Storgaard, Sorin Rugină, R. Greil, J. Hernandez Quero, Y van Delft, Andrew Hill, E. Voronin, Dan Turner, Philippe Morlat, N. Vetter, S. Maayan, Claudine Duvivier, Gerd Fätkenheuer, Andrea Antinori, J. Durant, Gaetano Filice, Stephan Marks, B. Gruzdev, A. Pronin, W. Schmidt, C. Stellbrink, Mark T. Nelson, Court Pedersen, Daniel Podzamczer, A. Streinu, Albrecht Stoehr, Gatell Jm, Armin Rieger, C. Miralles Alvarez, Chloe Orkin, G. Di Perri, L. Itzchak, B Clotet, Dénes Bánhegyi, D. Duiculescu, E. Shahar, Margaret A. Johnson, Adriano Lazzarin, M. Andreoni, Christine Katlama, Juergen K. Rockstroh, M Fisher, David Rey, G. Carosi, Pere Domingo, S. Erscoiu, C. Duvvier, Vadim Pokrovsky, Julie Fox, Christoph Stephan, A. Yakovlev, J. Feher, Stefan Esser, L. Cotte, Jose R. Arribas, Hansjakob Furrer
Publikováno v:
Fätkenheuer, G, Duvivier, C, Rieger, A, Durant, J, Rey, D, Schmidt, W, Hill, A, van Delft, Y, Marks, S, SENSE Study Team & Pedersen, C 2012, ' Lipid profiles for etravirine versus efavirenz in treatment-naive patients in the randomized, double-blind SENSE trial ', Journal of Antimicrobial Chemotherapy, vol. 67, no. 3, pp. 685-90 . https://doi.org/10.1093/jac/dkr533
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY
r-IIB SANT PAU. Repositorio Institucional de Producción Científica del Instituto de Investigación Biomédica Sant Pau
instname
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY
r-IIB SANT PAU. Repositorio Institucional de Producción Científica del Instituto de Investigación Biomédica Sant Pau
instname
Background: Etravirine is approved for use in treatment-experienced patients at a dose of 200 mg twice daily. Efavirenz has been associated with greater increases in serum lipids compared with other non-nucleosides in randomized trials of first-line